In 2023 ASCO, a number of research data will be presented

ASCO 2023, one of the most influential oncology clinical academic meetings in the world, will be held on June 2-6 (Eastern time) in Chicago, United States. For the first time, Szemsen Zeming, an innovative biopharmaceutical company under Szemsen Pharmaceutical Group (2096.HK) focused on the field of anti-cancer, set up a booth at ASCO to showcase the company's innovative drug research and development progress, and to discuss and exchange opportunities for collaborative innovation with attendees from around the world.

At this ASCO annual meeting, a total of 6 studies related to three innovative drugs, Cocela ®, Envida ® and Endu ®, have been included in the market product portfolio, involving small cell lung cancer, non-small cell lung cancer, triple negative breast cancer, stomach cancer, soft tissue sarcoma and other cancers. Data highlights are captured as follows:

Cocela ® (Treacilil) is an innovative chemotherapeutic bone marrow protection drug jointly developed by Cimen Pharmaceutical and G1 Company in the United States. It has been approved and marketed in both China and the United States. Cimen Zexing owns all the rights and interests of the indications for this product in the Greater China region.

Wall display: Early breast cancer patients with chemotherapy before using single dose qu raschig immune related antitumor efficacy Neoadjuvantsingle - dosetrilaciclibpriortocombinationchemotherapyinpatientswithearlytripl e-negativebreastcancer:Safety,efficacy,andimmunecorrelatedatafromaphase2study.

Abstract number: 603

Poster number: 433

Author: JeremyMeyerForce Professor, Duke University School of Medicine

This Phase II open-arm study (NCT05112536) used triacilil as neoadjuvant therapy in 24 patients with early-stage triple negative breast cancer (TNBC), followed by a single dose of triacilil plus intensive standard chemotherapy (AC/T), as well as appropriate immunotherapy or carboplatin, followed by radical surgery in each patient. The main objective of this study was to explore the immune-based mechanism of action after a single dose of treacilil. Data showed that pathological complete responses (pCR) were observed in 7 of 15 patients (47%) with available efficacy data, and pCR rates were 86% and 13% in PD-L1 positive and PD-L1 negative patients, respectively. Tumor microenvironment immunoassay showed that increased stromal tumor infiltrating lymphocytes and granulozyme B+ cells, and increased CD8+T cells at baseline of patient circulation may be PCR-related immune features.

Electronic paper: study real world music raschig, improve safety RealworldoutcomesoftrilaciclibinES small cell lung cancer PEA package - SCLC

Abstract Number: e20637

By JosephElijah, Professor, Roswell Park Comprehensive Cancer Center

Of the 78 patients with extensive small cell lung cancer, 34 received triacilil before receiving first-line PEA (attilizumab, carboplatin + etoposide) regimen for small cell lung cancer, and another 44 received PEA alone. Results showed erythrocyte transfusion requirements after treacilil treatment (3%vs.23%; P=0.02) and the incidence of grade 3-4 anemia (6%vs.25%; P=0.03) were significantly decreased and had statistical difference. The incidences of SN(3%), febrile neutropenia (FN) or hospitalization for infection (6%) in the treacilil group were numerically lower than those in the PEA group (18% and 11%), but did not reach a statistical difference (P=0.07; P=0.065). Survival outcomes (PFS and OS) were not statistically different between the two groups. This study supports the use of triacilil in combination with PEA for the treatment of ES-SCLC to improve treatment safety without negative effects on survival outcomes.

Enveda ® (Envollizumab) is an innovative tumor drug for subcutaneous injection of PD-L1 antibody in strategic cooperation with Thought Di Pharmaceutical and Corning & Jerry's. Enveda ® is responsible for the exclusive commercial promotion of the product in mainland China

Electronic Summary: Mr Wally single joint SOX resistance line treatment of advanced gastric cancer First - the new development of multicenter phase II clinical lineenvafolimabplusSOXchemotherapyforPD - L1positivemetastaticorrecurrentgastricadenoc arcinoma:Amulti-centre,single-armphaseIIclinicaltrial.

Abstract Number: e16029

Author: Professor Zhu Liangjun, Jiangsu Cancer Hospital

A total of 38 patients with advanced gastric adenocarcinoma were enrolled in this study (NCT05237349). After 6 cycles of subcutaneous injectable PD-L1 antibody drug Emvolizumab combined with SOX chemotherapy (oxaliplatin +S-1), Emvolizumab combined with S-1 maintenance therapy was administered. Among the 13 patients enrolled and treated, 8 were included in the efficacy analysis and 9 were included in the safety evaluation, with ORR of 50% and DCR of 87.5%. At present, the survival data is not mature. The most common treatment-related adverse events were elevated AST (75%), elevated ALT (65%), and leukopenia (42.5%). The data suggest that Envolizumab combined with chemotherapy is a promising and tolerable treatment option for patients with metastatic or recurrent gastric adenocarcinoma.

Wall display: Grace vader key clinical research of advanced soft tissue sarcoma ENVASARC: Apivotaltrialofenvafolimabandenvafolimabincombinationwithipilimumabinpatientswithadvancedor metastaticun-differentiatedpleomorphicsarcomaormyxofibro-sarcomawhohaveprogressedonpriorchemotherapy.

Author: Prof. RichardF.Riedel, Duke University Medical Center

Abstract Number: TPS11583

Poster number: 515a

ENVASARC(NCT04480502) is a pivotal international multicenter open-label, randomized, non-comparable, parallel cohort study of 160 patients with locally advanced unresectable or metastatic undifferentiated pleurosarcoma (UPS) and myxfibrosarcoma (MFS) who have failed prior treatment. Eighty of them received the subcutaneously injectable PD-L1 drug Emvolizumab and 80 received Emvolizumab in combination with the CTLA-4 antibody drug Ipilimumab. The primary study endpoint was the total response rate for each parallel cohort.

Endu ® (recombinant human vascular endostatin) is a pioneering cornerstone product and a classic angiogenesis inhibitor

Electronic Summary: Grace degree of joint PD - 1 a line in the treatment of non-small cell lung cancer in the real world data encouraging antibodypluschemotherapyasfirst EndostatinincombinationwithPD - 1 - lineregimenforEGFR/ALK - negat ive,advancedormetastaticnon-smallcelllungcancer:Areal-worldstudy

Abstract Number: e20564

Author: Zhang Guoqing, Professor of the First Medical Center of PLA General Hospital

In this study, 68 patients with locally advanced or distal metastatic non-small cell lung cancer (NSCLC) were treated with recombinant human endostatin combined with PD-1 antibody and chemotherapy. Median follow-up time was 21.4 months, median PFS and OS were 22.0 and 31.0 months, respectively. At the data cut-off, 33 patients (48.5%) had not progressed and 24 patients (35.3%) had died. The short-term clinical efficacy was evaluated after 2 consecutive treatment cycles, and the overall response rate (ORR) was 72.06% (complete response [CR], n=3; Partial response [PR], n=46), disease control rate was 95.59% (CR, n=3; PR, n=46; The disease was stable, n=16). ORR(89.2%vs.51.6%), median PFS (23.4 vs.13.2 months), and median OS (NRvs.18.0 months) were significantly better in stage ⅢB/ⅢC patients than in stage Ⅳ NSCLC patients (P≤0.001). In addition, the median PFS (8.0 months vs.22.5 months, P=0.004) and OS (13.0 months vs.31.0 months, P=0.027) were significantly shorter in patients with BMS than in patients without BMS.

Electronic Summary: Grace degree combined immunotherapy second-line treatment of advanced non-small cell lung cancer clinical outcome is better than that of immune MDT Immunotherapycombinedwithrh - endostatinimprovedclinicaloutcomesoverICIspluschemotherapyfo rsecond-linetreatmentofadvancedNSCLC.

Abstract Number: e21133

Author: Professor Chen Li, Department of Oncology, the First Affiliated Hospital of Nanchang University

This retrospective study compared the efficacy and safety of immunocheckpoint inhibitors combined with recombinant human endostatin (Endo ®) and immunocheckpoint inhibitors combined with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). Data showed a median PFS of 7.10 months in the combined Endodu group and 5.13 months in the combined chemotherapy group. The rates of grade 3 or 4 treatment-related adverse events were 7.5% and 25.0%, respectively. ORR and DCR were 35.0% and 92.5% in the combined Endodu group, while ORR20.8%(P=0.137) and DCR were 77.1%(P=0.049) in the combined chemotherapy group. The 1-year survival rate of the combined Endo-do group was 69.4%, higher than that of the combined chemotherapy group (61.4%).